Company news
Innovation Pharmaceuticals Inc. (OTC:IPIX) news
Innovation Pharmaceuticals Inc. news releases on 6ix. Latest, Aug 15, 2017: Innovation Pharmaceuticals to Discuss Recent Positive Clinical Results in IBD…
Press releases — page 4
Innovation Pharmaceuticals to Discuss Recent Positive Clinical Results in IBD and Upcoming Milestones in Oral Mucositis and Psoriasis Trials at BioCentury’s “NewsMakers” Conference
August 15, 2017
Innovation Pharmaceuticals Completes Patient Enrollment in Phase 2 Study of Brilacidin for the Prevention of Severe Oral Mucositis
August 7, 2017
Innovation Pharmaceuticals Phase 2 PoC Trial for Inflammatory Bowel Disease Achieves Induction of Remission in a Majority of Patients Treated with Brilacidin
July 13, 2017
Innovation Pharmaceuticals Completes Treatments in Phase 2 PoC Trial for Induction of Remission in Inflammatory Bowel Disease; Topline Results with Endoscopic Response to Be Presented July 13, 2017
June 26, 2017
Innovation Pharmaceuticals Name and Ticker Change Effective, Replay of Shareholder Conference Call Available
June 9, 2017
Cellceutix Announces Company Name Change to Innovation Pharmaceuticals Inc.
June 7, 2017
Cellceutix Anti-Cancer Drug Candidate’s p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the 2017 European Hematology Association Annual Meeting
May 30, 2017
Cellceutix Completes Patient Enrollment of Final Cohort in Phase 2 Trial of Brilacidin for Inflammatory Bowel Disease; Topline Results Anticipated in July
May 18, 2017
Cellceutix Provides Corporate Update; Significant Milestones Ahead as Multiple Mid-Phase Clinical Trials Set to Conclude
May 10, 2017
Cellceutix Announces Details for Upcoming Investor and Shareholder Presentations
April 19, 2017
Cellceutix CEO Discusses Brilacidin Following Interim Trial Results for Treating Oral Mucositis and Inflammatory Bowel Disease
April 10, 2017
Cellceutix AACR Poster Presents Data Supporting Kevetrin Modulation of p53 in Multiple Human Ovarian Cancer Cell-lines and Corresponding Xenograft Tumors
April 3, 2017
Cellceutix Reports Very Encouraging Interim Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral Mucositis (OM) in Head and Neck Cancer Patients; High Potential for Preventative Treatment
March 27, 2017
Cellceutix Releases Favorable Topline Findings as Part of Interim Analysis of Phase 2 Drug Candidate Brilacidin for the Treatment of Inflammatory Bowel Disease
March 21, 2017
Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel Disease
March 16, 2017
Cellceutix Releases Preliminary Efficacy and Safety Data in Interim Analysis of First Two Cohorts in Phase 2 Trial of Brilacidin for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
March 8, 2017
Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent
March 3, 2017
Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
February 22, 2017
Cellceutix Reports on Q2 Fiscal 2017, Prepares for Important Clinical Milestones
February 16, 2017
Cellceutix Announces Initiation of Main Clinical Site for Phase 2a Trial of p53 Drug Candidate Kevetrin in the Treatment of Platinum-Resistant/Refractory Ovarian Cancer
February 10, 2017
Cellceutix’s Brilacidin Demonstrates Promise in Treating Ulcerative Colitis Supported by Endoscopic Assessment, Patient-Reported Outcomes
January 23, 2017
Cellceutix Strongly Denounces Criminal Enterprise Mako Research, Who Published “Fake News” Full of Lies and Innuendo
January 17, 2017
Cellceutix Completes Enrollment in Second of Three Planned Cohorts in Phase 2 Clinical Trial of Brilacidin for Inflammatory Bowel Disease
January 17, 2017
Cellceutix to Present at Biotech Showcase 2017; Brilacidin for Oral Mucositis Nears Interim Results
January 4, 2017
Cellceutix Wishes Shareholders Happy Holidays, Prepares for 2017 Focused on Partnerships
December 22, 2016
Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis Initiated and Open for Screening
December 19, 2016
Cellceutix Reports Advances in Developing Kevetrin as an Oral Ovarian Cancer Treatment; Company Seeks to Develop World’s First p53-Modulating Oral Cancer Drug
December 15, 2016
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis
December 7, 2016
Cellceutix Provides Corporate Update and Reports Q1 Fiscal 2017 Financial Results
November 14, 2016
Cellceutix Announces Business Update Call at 10AM Eastern on November 15
November 9, 2016
Cellceutix Begins Phase 2b Clinical Trial of Oral Prurisol in Moderate-to-Severe Chronic Plaque Psoriasis
October 31, 2016
Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications
October 26, 2016
Cellceutix Phase 2 Trial Initial Data Shows Potential of Brilacidin as a Novel Anti-Inflammatory Drug Candidate for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
October 10, 2016
Cellceutix Announces Appointment of Vice President for Regulatory Affairs
September 16, 2016
Cellceutix Corporation Provides Business Update and Timeline of Upcoming Milestones
September 13, 2016
Cellceutix Corporation to Present at Upcoming Conferences
September 7, 2016
Cellceutix Further Expands Its Senior Management Team With the Addition of an Industry Veteran
August 30, 2016
Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data
August 3, 2016
Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
July 21, 2016
Cellceutix Receives Update on First Patient Enrolled in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative Proctitis
July 18, 2016
OTC Markets Group Welcomes Newly Verified OTCQB Companies – July 13
July 13, 2016
Cellceutix to Initiate Phase 2b Trial of Prurisol for Chronic Plaque Psoriasis
July 7, 2016
Cellceutix Corporation Announces Industry Veteran Arthur P. Bertolino, MD, PhD, MBA Joins Company as President and Chief Medical Officer
June 30, 2016